Summary
Core view: Supriya Lifescience grew Q1 FY27 revenue 30.8% year-on-year, but net profit fell 30.9% as EBITDA margin compressed to 25.0% from 35.6% and capacity utilisation fell to 70% from 74%. This was a genuinely weak quarter on profitability, not a strong one, even though the top line grew; cost recovery and utilisation improvement are the key things to watch before assuming a turnaround.
Supriya is an API manufacturer focused on the anaesthetic and vitamin segments, with a high export share. The anaesthetic segment (48% of Q1 FY27 revenue) and vitamins (17%) are the largest contributors, with 81% of revenue from exports.
Q1 FY27 Snapshot
Revenue₹189.75 Cr+30.8% YoY
PAT₹24.04 Cr-30.9% YoY
EBITDA margin25.0%vs 35.6% YoY
Capacity utilisation70%vs 74% YoY
| Segment | Q1 FY27 revenue mix |
|---|---|
| Anaesthetics | 48% |
| Vitamins | 17% |
| Exports (total) | 81% |
Business Quality And Mix
Strengths
- Strong revenue growth (+30.8% YoY) shows continued demand.
- High export mix (81%) reflects regulated-market approvals.
- Leadership position in select anaesthetic APIs.
- New product launches planned in anaesthetic and ADHD segments.
Constraints
- EBITDA margin compressed sharply to 25.0% from 35.6% YoY.
- Capacity utilisation fell to 70% from 74%.
- Net profit declined 30.9% YoY despite revenue growth.
- Cost pressures were not fully offset by pricing or volume.
Growth Drivers And Capacity Economics
FY27 revenue target~₹1,000 CrManagement commentary
Export share81%Q1 FY27
Capacity utilisation70%Room to improve
Management has cited an FY27 revenue target of about ₹1,000 crore, supported by new product launches in the anaesthetic and ADHD segments and ongoing capex at the Ambernath and Patalganga facilities. The near-term priority is recovering margin and utilisation, not just growing revenue.
Management Guardrails And Credibility
| Objective | Target | Assessment |
|---|---|---|
| Revenue target | ~₹1,000 Cr for FY27 | Achievable if growth continues at a similar pace to Q1, but margin recovery is now the more important test. |
| Margin recovery | Not formally guided | EBITDA margin needs to recover from 25.0% toward the historical mid-30s% range for earnings quality to improve. |
| Capacity utilisation | Improve from 70% | Utilisation improvement would help operating leverage and margin recovery. |
Financial Quality
EBITDA margin25.0%Down from 35.6% YoY
PAT margin12.7%Down from 24.0% YoY
Capacity utilisation70%Down from 74% YoY
Export mix81%High regulated-market exposure
| Quality test | Reading | Interpretation |
|---|---|---|
| Earnings quality | PAT -30.9% YoY despite revenue +30.8% | A genuine margin and utilisation problem, not merely a high base-effect; this was a weak quarter on profitability. |
| Margin trend | EBITDA margin 25.0% vs 35.6% YoY | A more than 10-point compression is material and needs explicit management explanation and recovery evidence. |
| Capacity utilisation | 70% vs 74% YoY | Lower utilisation on higher revenue suggests cost or product-mix pressure rather than a simple volume problem. |
Valuation
Key Risks
- Further margin compression if cost pressures persist.
- Capacity utilisation not recovering as expected.
- Export/regulated-market demand or pricing pressure.
- Delays in anaesthetic/ADHD product launches.
- Currency and raw-material cost volatility.
Projection: Next 2-4 Quarters
Investor Watchlist
- EBITDA margin recovery trend versus the Q1 FY27 low of 25.0%.
- Capacity utilisation trend versus 70%.
- Progress on new anaesthetic and ADHD product launches.
- Export revenue mix and pricing.
- Capex progress at Ambernath and Patalganga.